Wednesday, 9 November 2011

Natalizumab (Tysabri) treatment for children with MS


Source MS Trust:

A study of 35 children under the age of 18 treated for 23 months with natalizumab (Tysabri) found that the treatment was safe, well tolerated and effective in suppressing disease activity.  Read more here.